A case of long-term survival following hepatectomy for liver metastasis of Merkel cell carcinoma by unknown
Shoda et al. Surgical Case Reports  (2015) 1:30 
DOI 10.1186/s40792-015-0015-7CASE REPORT Open AccessA case of long-term survival following hepatectomy
for liver metastasis of Merkel cell carcinoma
Katsutoshi Shoda1, Hisashi Ikoma1*, Yusuke Yamamoto1, Osamu Kinoshita1,2, Ryo Morimura1, Hirotaka Konishi1,
Yasutoshi Murayama1, Shuhei Komatsu1, Atsushi Shiozaki1, Yoshiaki Kuriu1, Masayoshi Nakanishi1,
Daisuke Ichikawa1, Hitoshi Fujiwara1, Kazuma Okamoto1, Chohei Sakakura1, Toshiya Ochiai3, Hiroki Taniguchi4,
Satoshi Yasukawa2 and Eigo Otsuji1Abstract
Background: Merkel cell carcinoma (MCC) is a rare endocrine tumor that presents as a rapidly growing skin nodule
of the body, and it is aggressive with regional nodal and distant metastases without clearly defined treatment. There
are no reports of long survivors among patients with liver metastasis of MCC. The current case was a patient who
underwent surgical resection for liver metastasis of Merkel cell carcinoma.
Case presentation: This case describes a 73-year-old female with a papule on the dorsal side of the right third
finger and liver tumor. The papule of the right third finger was histologically diagnosed as MCC by the skin biopsy. She
underwent extensive resection and lymph node dissection of the right third finger and partial resection of the liver. The
liver tumor was histologically diagnosed as liver metastasis of MCC. The patient remains well without any evidence of
tumor recurrence more than 5 years after surgery.
Conclusions: This is the first report of a long-term survival of more than 5 years following liver metastasis of MCC,
which was surgically resected. Patients with small and solitary metastatic liver tumor of MCC may have a chance for a
long-term survival following the hepatic resection.
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Merkel cell carcinoma (MCC) is a relatively rare neuro-
endocrine cancer in the skin with an age-adjusted inci-
dence of less than 0.5 per 100,000 person-years [1].
Patients with MCC tend to have a poor prognosis with a
5-year survival rate of approximately 50% even after
curative tumor resection, because of the high frequency
of early metastasis to the lymph nodes, lung, skin, and
central nervous system [2]. Clinically localized MCC is
treated with wide surgical excision of the primary tumor
[3]; however, the therapeutic strategy against distant me-
tastasis of MCC has not yet been standardized. Patients
with liver metastasis of MCC rarely have a chance
undergoing hepatectomy, and there are no reports of
any long-term survivors of liver metastasis of MCC after* Correspondence: ikoma@koto.kpu-m.ac.jp
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was a patient who underwent surgical resection for liver
metastasis of MCC, and this patient has survived with-
out recurrence for more than 5 years after hepatectomy.Case presentation
Clinical summary
A 73-year-old female was found to have a papule, meas-
uring 20 mm in diameter, on the dorsal side of the right
third finger. Laboratory data indicated that her alanine
aminotransferase, carcinoembryonic antigen, carbohy-
drate antigen 19-9, squamous cell carcinoma antigen,
neuron specific enolase, and alpha-fetoprotein were
within normal limits, but the serum levels of protein
induced by vitamin K absence or antagonist II were ele-
vated to 51 mAU/ml. The serum markers for hepatitis B
and hepatitis C were negative.
Abdominal computed tomography (CT) revealed an
ill-defined mass, measuring 20 mm in diameter on livern open access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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phase and ring-shaped enhanced in the portal phase
(Figure 1). The tumor appeared as a well-defined
hypointense mass in the hepatocyte-specific phase on
gadoxetate disodium-enhanced magnetic resonance
imaging (Figure 2). Positron emission tomography/
computed tomographic scans showed the uptake of 2-
[fluorine-18] fluoro-2-deoxy-D-glucose in liver segment
IV and the right third finger (Figure 3). She underwent a
skin biopsy of the papule on the right third finger in a
local hospital, and it was histologically diagnosed as MCC.
MCC of the right third finger and metastatic tumor of the
liver were suspected. She underwent extensive resection
and lymph node dissection of the right third finger at a
local hospital. All resection margins were negative and
there was no lymph node metastasis.
She was referred to our hospital, and partial resection
of liver segment IV was performed under a preoperative
diagnosis of the metastatic liver tumor of the MCC. The
patient started adjuvant chemotherapy 6 weeks after
hepatectomy, and she has received cisplatin (110 mg/
body) and etoposide (145 mg/body) for 12 weeks. The
patient remains well without any evidence of tumor re-
currence more than 5 years after surgery.
Pathological findings
A histopathological examination of the specimen from the
right third finger showed cells with scanty cytoplasm and
small round nuclei, proliferating in the trabecular and
clumps with fibrosis. The nuclei were clear and pale with
delicate chromatin. The tumor was immunohistochemicallyFigure 1 Preoperative abdominal computed tomography. Preoperative
arrowhead), 20 mm in diameter, on the liver segment IV (A), which was we
portal phase (C).positive for neuroendocrine markers (synaptophysin and
CD56), cytokeratin marker (CAM5.2), and CK20. These
findings suggested that pathological diagnosis was MCC on
the right third finger.
The resected liver tumor measured 15 × 13 mm
(Figure4). The cut surface of the tumor showed a
yellowish-white, elastic-hard solid component and clear
boundary line between the surrounding liver tissue and
tumor. There were cells with scanty cytoplasm and
small round nuclei, proliferating in a trabecular pattern
and clumps with fibrosis. The nuclei were clear pale
with delicate chromatin. The edge of the tumor showed
a perinuclear dot-staining pattern, which is typical find-
ing of MCC. The tumor component was similar to the
primary tumor of MCC tumor of the right third finger.
Neuroendocrine markers (synaptophysin, chromogra-
nin A, and CD56), cytokeratin marker (CAM5.2), neu-
rofilament, and CK20 were immunohistochemicaly
positive, and S100 was negative. Figure 5A, B shows
representative findings of hematoxylin-eosin staining
and CK20 immunohistochemistry with metastatic liver
tumor, respectively. These findings suggested that the
pathological diagnosis was liver metastasis of MCC.
The tumor was not exposed on either the surface or
the cut surface of the liver. Additional pathological re-
sults revealed that primary tumor showed a low prolif-
erative labeling index (Ki-67: 2.1%), and metastatic liver
tumor showed a high proliferative index (Ki-67: 26.0%).
Figure 6A, B shows representative findings of Ki-67
staining with primary tumor and metastatic liver
tumor, respectively.abdominal computed tomography revealed an ill-defined mass (white
ll-stained in the arterial phase (B), and ring-shaped enhanced in the
Figure 2 Gadoxetate disodium-enhanced magnetic resonance imaging. Gadoxetate disodium-enhanced magnetic resonance imaging showed a
well-stained mass (white arrowhead) in the arterial phase (A) and a well-defined hypointense mass in the hepatocyte-specific phase (B).
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MCC is a rare, aggressive neuroendocrine tumor that is
usually found in the dermis and can extend into the sub-
cutaneous tissue or involve the overlying epidermis [4].
Patients with distant metastasis have a poor prognosis
due to the high propensity for local recurrence and dis-
tant metastasis [5]. Median overall survival with MCC
was 3.6 years for local disease, 2.0 years for regional dis-
ease, and 1.2 years for distant metastasis in multicenter
cohort study [6]. This is the first case of long survival ofFigure 3 Positron emission tomography/computed tomographic scans.
the uptake of 2-[fluorine-18] fluoro-2-deoxy-D-glucose in the right third fingermore than 5 years after hepatectomy for liver metastasis
of MCC without recurrence.
Gastroenteropancreatic neuroendocrine tumor is gen-
erally classified by mitotic count and Ki-67 labeling
index (Ki-67 LI), according to the WHO 2010 classifica-
tion. Some researcher recently suggested that the higher
Ki-67 LI might be associated with unfavorable onco-
logical outcome [7]. In this study, the Ki-67 LI of pri-
mary MCC was 2.1% and that of liver metastasis was
26.0%. This result suggests two important implications.Positron emission tomography/computed tomographic scans showed
(white arrowhead, A) and liver segment IV (white arrowhead, B).
Figure 4 Gross view of liver tumor. Gross view of liver tumor shows a yellowish-white, elastic-hard solid component and clear boundary line
between the surrounding liver tissue and tumor.
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metastasis. Second, the complete resection for liver me-
tastasis may contribute to the long survival, even if the
tumor has high Ki-67 LI.
MCC sometimes develops metastasis to the lymph
nodes, kidney, small bowel, pancreatic body, adrenal
glands, abdominal wall, bone marrow, and parathyroid
glands [2]. The frequency of liver metastases is relativelyFigure 5 Histological appearance of high-magnification view of the li
liver tumor (A, hematoxylin and eosin stain × 400) and immunohistochemi
small round nuclei, proliferating in the trabecular and clumps with fibrosis.
edge of the tumor was observed in the staining of perinuclar dot pattern,rare [8], and patients with liver metastasis of MCC rarely
have a chance undergoing hepatectomy. Skagias et al. re-
ported a case that underwent extended right hepatec-
tomy for the liver metastasis of MCC, 15 cm in
diameter, which is the only report of hepatic resection
for liver metastasis of MCC [9]. They provided no data
of the prognosis after hepatectomy. The current meta-
static tumor of the liver was solitary, and the maximumver tumor. Histological appearance of high-magnification view of the
cal expression (×200) of CK20 (B). (A) Cells with scanty cytoplasm and
Nuclei are clear pale with delicate chromatin. (B) CK20 is positive. The
which is typical finding of MCC.
Figure 6 Representative findings of Ki-67 staining with primary tumor and metastatic liver tumor. Ki-67 immunohistochemical findings in
primary MCC (A) and metastatic liver tumor (B). Ki-67 LI of primary MCC was 2.1% and that of liver metastasis was 26.0%.
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make any definite comments; however, the current re-
sults suggest that patients with small and solitary meta-
static liver tumor of MCC may achieve long-term
survival following hepatic resection, and hepatic resec-
tion may be justified for these patients. Thus, careful
examination of the liver is important after primary resec-
tion of MCC, and early detection of the liver metastasis
of MCC is crucial.
The typical chemotherapeutic regimens of MCC are
similar to those for small cell lung cancer and neuroen-
docrine tumors in other locations [1,10]. The optimal
chemotherapy regimen for patients with MCC remains
controversial, although most authors have prescribed
combination chemotherapy regimens [8]. Some common
regimens include cisplatin with etoposide, cytoxan with
adriamycin and vincristine, cisplatin with adriamycin,
and streptozocin with 5- fluorouracil [11,12]. The
reported median survival time from initiation of chemo-
therapy for distant metastasis of MCC is approximately
9 months [5,13]. The current patient received chemo-
therapy with cisplatin and etoposide for 12 weeks, begin-
ning 6 weeks after hepatectomy for liver metastasis of
MCC. Although the current patient received chemother-
apy according to the previous report [11], MCC was
initially thought to be resistant to chemotherapy. In re-
cent study, it was suggested that treating with adjuvant
chemotherapy was not associated with improved MCC
outcomes in large cohort [6]. On the other hand, in
some previous reports, adjuvant radiation therapy plays
a significant role in MCC treatment by reducing recur-
rence and improving local/regional control of disease[3,14,15]. Moreover, some authors mentioned that neo-
adjuvant chemotherapy led to local control and allowed
curative surgery [16], resulting in long-term survival,
whereas the clinical results of these therapies cannot be
verified without long survivors. We think that a curative
surgery with enough margins is the best choice contrib-
uting to improvement of the outcome, and further pro-
spective study with neoadjuvant and adjuvant therapy
will be needed.
Conclusions
In conclusion, this is the first report of a long-term sur-
vival of more than 5 years following liver metastasis of
MCC, which was surgically resected. Patients with small
and solitary metastatic liver tumor of MCC may have a
chance for a long-term survival following the hepatic
resection.
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